PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform, Expediting its IND Submission to the FDA
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, announces today that it has amended its master sponsored agreement with Miami University based in Oxford, Ohio (the
Amended Agreement ) to extend and expand the research efforts of the laboratory of Dr. J. Andrew Jones in the Department of Chemical, Paper, and Biomedical Engineering (the
Jones Lab ), to include additional research efforts of the laboratory of Dr. Matthew McMurray in the Department of Psychology (the
Published: Apr 26, 2021
OSE Immunotherapeutics to receive up to €315 million in potential milestones,
including a €7 million upfront, and tiered royalties on sales.
NANTES, France and CARY, N.C. , April 26, 2021 (GLOBE NEWSWIRE) OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Veloxis Pharmaceuticals A/S
a subsidiary of Asahi Kasei, today announced a global license agreement granting Veloxis Pharmaceuticals worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases. Through this license agreement, Veloxis plans to develop FR104 to provide a new therapeutic option for prophylaxis of organ rejection in patients receiving a solid organ transplant.
PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors
Mr. Oliver joins PsyBio bringing over 25 years of executive pharmaceutical experience having held various senior positions at Otsuka, Wyeth and Johnson & Johnson
News provided by
Share this article
Share this article
PsyBio or the
Company ), a biotechnology company pioneering the next generation of targeted psychoactive medications, is pleased to announce the appointment of Mr. Bob Oliver to the Company s board of directors (the
Board ), effective immediately. The Company is developing a platform technology that produces tryptamines, such as psilocybin and its intermediates, for intended therapeutic use. Mr. Oliver has extensive experience in launching pharmaceutical products into global markets offering invaluable depth to our team.
Home / Top News / BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)
– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone
– Plinabulin’s MoA is distinct from, yet complementary to that of G-CSF, acting in Week 1 of the chemotherapy cycle, where over 75% of CIN-related complications occur, with G-CSF acting in Week 2
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope responses.
CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants.
CoVepiT, as second-generation vaccine, potentially provides long-term cellular immunity with memory T cells.
Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the Belgian Federal Agency for Medicines and Health Products (
Agence Fédérale des Médicaments et des Produits de Santé AFMPS) and the Belgian Ethics Committee approved the Phase 1 trial evaluating its COVID-19 vaccine, named CoVepiT, on 48 healthy volunteers. First subjects are expected to be enrolled shortly.